Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

CAR Treg cells: prime suspects in therapeutic resistance

Nature Medicine volume 28, pages 1755–1756 (2022)Cite this article

Subjects

Using comprehensive single-cell profiling, two studies reveal the molecular phenotypes of CAR T cells associated with durable response in patients with lymphoma, and highlight the role of CAR regulatory T cells in mediating resistance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: CAR Treg cells are associated with poor responses to anti-CD19 CAR T cell therapy in patients with lymphoma.

References

  1. Neelapu, S. S. et al. N. Engl. J. Med. 377, 2531–2544 (2017).

    Article  CAS  Google Scholar 

  2. Jacobson, C. A. et al. Lancet Oncol. 23, 91–103 (2022).

    Article  CAS  Google Scholar 

  3. Schuster, S. J. et al. N. Engl. J. Med. 380, 45–56 (2019).

    Article  CAS  Google Scholar 

  4. Haradhvala, N. J. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01959-0 (2022).

    Article  PubMed  Google Scholar 

  5. Good, Z. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01960-7 (2022).

    Article  PubMed  Google Scholar 

  6. Deng, Q. et al. Nat. Med. 26, 1878–1887 (2020).

    Article  CAS  Google Scholar 

  7. Jackson, Z. et al. Cancer Discov. 12, 1886–1903 (2022).

    Article  Google Scholar 

  8. Lee, J. C. et al. Cancer Res. 71, 2871–2881 (2011).

    Article  CAS  Google Scholar 

  9. Florek, M. et al. PLoS ONE 10, e0145763 (2015).

    Article  Google Scholar 

  10. Humblet-Baron, S. et al. J. Allergy Clin. Immunol. 138, 200–209 (2016).

    Article  CAS  Google Scholar 

  11. Lichtenstein, D. A. et al. Blood 138, 2469–2484 (2021).

    Article  CAS  Google Scholar 

  12. Scholler, N. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01916-x (2022).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This was work is supported by the MD Anderson Cancer Center support grant P30 CA016672 from the US National Institutes of Health.

Author information

Authors and Affiliations

  1. Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Neeraj Saini & Sattva S. Neelapu

  2. Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Neeraj Saini

Authors
  1. Neeraj Saini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sattva S. Neelapu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sattva S. Neelapu.

Ethics declarations

Competing interests

S.S.N. received research support from Kite/Gilead, BMS, Cellectis, Poseida, Allogene, Unum Therapeutics, Precision Biosciences, and Adicet Bio; served as Advisory Board Member/Consultant for Kite/Gilead, Merck, Novartis, Sellas Life Sciences, Athenex, Allogene, Incyte, Adicet Bio, BMS, Legend Biotech, Bluebird Bio, Fosun Kite, Sana Biotechnology, Caribou, Astellas Pharma and Morphosys; has received royalty income from Takeda Pharmaceuticals; has stock options from Longbow Immunotherapy; and has intellectual property related to cell therapy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saini, N., Neelapu, S.S. CAR Treg cells: prime suspects in therapeutic resistance. Nat Med 28, 1755–1756 (2022). https://doi.org/10.1038/s41591-022-01998-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-01998-7

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research